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a b s t r a c t
Background: In Denmark, live measles, mumps, and rubella vaccine (MMR) is associated with a reduced
risk of infectious disease admissions, particularly for lower respiratory tract infections. In low-income
countries, simultaneous vaccination (i.e. vaccination at the same visit) with live and inactivated vaccines
may increase child mortality compared with the live vaccine alone. We examined the hypothesis that
simultaneous administration of MMR and the inactivated DTaP-IPV-Hib vaccine compared with MMR
alone is associated with higher incidence of infectious disease admissions.
Methods: Nationwide, retrospective, register based cohort study of 520,859 children born in Denmark
1997–2006, who were followed from 15 months to 4 years of age. Incidence rate ratios (IRRs) of hospital
admissions were estimated by Cox regression and adjusted for background factors including exact age.
Results: By 2 years of age, 4965 children had simultaneous MMR and DTaP-IPV-Hib as their most recent
vaccination. Compared with MMR alone, simultaneous administration was associated with a higher rate
of lower respiratory tract infections (adjusted incidence rate ratio (IRR), 1.27; 95% confidence interval
(CI), 1.13–1.42). There was no effect on other infections. Overall, simultaneous administration was asso-
ciated with a 7% (95% CI, 0–15%) increase in infectious disease admissions.
Conclusions: Simultaneous administration of MMR and DTaP-IPV-Hib compared with MMR alone may
increase the rate of hospital admissions related to lower respiratory tract infections. These findings
require replication in other high-income settings.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
We have previously shown that the rate of infectious disease
admissions was related to the type of vaccine Danish children most
recently had received. The live MMR-vaccine against measles,
mumps, and rubella as the most recent was associated with
reduced rate of infectious disease admissions compared with the
inactivated DTaP-IPV-Hib-vaccine against diphtheria, tetanus, per-
tussis (acellular), polio, and Haemophilus influenzae type b [1]. The
association was particularly strong for lower respiratory tract
infections. This finding supports evidence from randomized trials
in low-income countries that live vaccines like measles vaccine
have non-specific beneficial effects on the immune system by
reducing infectious disease mortality more than expected from
prevention of measles infections [2–4]. It has been proposed that
non-specific effects of vaccines could be related to cross-
protective antibodies or trained innate immunity [2,4,5].
The sequence and combination of vaccines may be very impor-
tant for the magnitude and direction of the overall mortality and
morbidity effects. Observational studies from low-income
countries have found that compared with measles vaccine alone
http://dx.doi.org/10.1016/j.vaccine.2016.11.005
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simultaneous administration (i.e. vaccination at the same visit) of
the live measles vaccine and the inactivated DTP-vaccine against
diphtheria, tetanus, and pertussis might be associated with higher
mortality [6–8]. If the combination of live and inactivated vaccines
has negative health effects compared with the live vaccine alone, it
could have important consequences for health also in high-income
countries. Some countries like Germany and Latvia administer
MMR together with DTaP-IPV-Hib [9]. In the USA, MMR is recom-
mended between 12 and 15 months of age as are several inacti-
vated vaccines [10]. In countries that do not recommend
simultaneous administration of live and inactivated vaccines many
children receive the vaccines at the same visit if coming late for
vaccinations.
In the present nationwide register based cohort study we tested
the hypothesis that compared with MMR administered alone,
simultaneous administration of MMR and DTaP-IPV-Hib is associ-
ated with higher rate of infectious disease admissions among
Danish children aged 15 months to 4 years.
2. Methods
In Denmark all residents are assigned a unique personal identi-
fication number and are registered with date of birth and where-
abouts in the Danish Civil Registration System [11] enabling
identification of the study cohort. We included children who were
born in Denmark between 1 January 1997 and 30 April 2006 and
who were alive and living in Denmark at 15 months of age; further
inclusion criteria are displayed in Fig. 1. The included cohort was
recommended three doses of the DTaP-IPV-Hib vaccine at 3, 5,
and 12 months of age and MMR at 15 months of age. The MMR
vaccine consisted of Enders Edmonston, Jeryl Linn, and Wistar RA
27/3. Furthermore, three doses of oral polio vaccine (OPV) were
recommended at 2, 3, and 4 years of age until 1 July 2001, thus it
was mainly the birth cohorts 1997–1999 who had received OPV.
The seven-valent pneumococcal conjugate vaccine was introduced
on 1 October 2006; children born after 30 April 2006 were recom-
mended a catch-up program and were not included in the present
study [12].
All national Danish registries record the unique personal identi-
fication number [13] making it possible to retrieve additional
information about the cohort as described below. The study was
approved by the Danish Data Protection Agency.
2.1. Vaccinations
In Denmark, all recommended childhood vaccinations are
administered free-of-charge by the general practitioners. For the
purpose of reimbursement, vaccination information is reported to
the Danish National Health Service Register [14]. Before 1997, all
vaccines were registered on the personal identification number
of the parents, but thereafter they were reported on the child’s
own personal registration number. Some childhood vaccines were
still registered on parents (3.4%), but we have assigned such vacci-
nes to the child who was closest to the recommended age for that
vaccine.
2.2. Infectious disease hospital admissions
The Danish National Patient Register contains information
about discharge diagnoses, which are coded according to the tenth
revision of the International Classification of Diseases [15]. We
identified date of admission and discharge for all inpatient contacts
with a primary or secondary discharge diagnosis of any infection as
previously described [1] and also given in Supplemental Table 1. In
Denmark, emergency departments are rarely used for infectious
diseases, because primary care service is available for 24 h, seven
days a week to deal with infectious diseases [16]. As primary care
has limited diagnostic tools like acute blood tests and X-rays, chil-
dren with severe infections are usually admitted to the free-of-
charge hospitals’ paediatric wards for further diagnostics and mon-
itoring; the mildest cases are often discharged the same day.
2.3. Other register based information
From the Danish National Patient Register we also obtained
information on previous admissions, emergency room visits due
to accidents and chronic diseases coded according to Kristensen
et al. [17]. We defined inclusion and follow-up with information
Fig. 1. Flowchart of inclusion in the study. Abbreviations: DTaP-IPV-Hib, vaccina-
tion against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus
influenzae type b; MMR, vaccination against measles, mumps, and rubella. Notes:
Infectious disease admissions are counted from the latest of the following events
15 months of age, received the first dose of either DTaP-IPV-Hib or MMR and until
date of censoring for the children included in the study or until 4 years of age for the
children excluded from the study. a DTaP-IPV or Hib alone (N = 18,149; 50.3%), not
recommended combination of vaccines (N = 7113; 19.7%), fourth dose of DTaP-IPV-
Hib (N = 6982; 19.4%), booster dose against different combinations of diphtheria,
tetanus, pertussis (acellular), and polio (N = 1972; 5.5%), whole cell pertussis
vaccine (N = 989; 2.7%), OPV (N = 500; 1.4%), second dose of MMR (N = 357; 1.0%)
and pneumococcal conjugate vaccine (N = 2, 0.0%). b Some children had missing
information on more than one variable. The number of children with missing
information on each variable and in parentheses the percentage among the total
number of children with missing information was: 23,391 (53.5%) with missing
information on maternal smoking during pregnancy, 20,024 (45.8%) with missing
information on educational level for the female adult in the household, 4698
(10.7%) with missing information on birth weight, 3610 (8.3%) with missing
information on gestational age, 3371 (7.7%) with missing information on household
income, 337 (0.8%) with missing information on parental place of birth, 330 (0.8%)
with missing information on maternal age at birth of the child, 200 (0.5%) with
uncertain vaccine allocation for twins or triplets, and 100 (0.2%) with missing
information on population density.
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on births, deaths, and emigration from the Danish Civil Registra-
tion Systemwhich also contain information about a child’s parents,
siblings, and household [11]. Information about maternal smoking
during pregnancy, mode of delivery, birth weight, and gestational
age was obtained from the Danish Medical Birth Register [18].
Information on household equivalence income [19], and maternal
education [20] was obtained from Statistics Denmark.
2.4. Follow-up
We started follow-up at 15 months of age, when MMR was rec-
ommended, or from the date when a child received the first dose of
either DTaP-IPV-Hib or MMR if it occurred after 15 months of age.
The children were followed until the earliest of the following
events: 4 years of age, administration of other vaccines than
DTaP-IPV-Hib1-3 or MMR1, death, migration, unknown where-
abouts for the Danish authorities, uncertain vaccine allocation, or
end of the study on 1 January 2009.
Factors related to receiving vaccines out-of-sequence may also
be related to the risk of admissions for infectious diseases. There-
fore, we defined a subgroup of children, the ‘‘DTaP-IPV-Hib-2-sub
group”, who had been compliant with the vaccination program
up to DTaP-IPV-Hib-2, and then subsequently received vaccines
out-of-sequence – either simultaneous MMR and DTaP-IPV-Hib3
or MMR alone instead of the recommended DTaP-IPV-Hib3 alone.
We redid some of the analyses in the ‘‘DTaP-IPV-Hib-2-subgroup”
to minimise the risk of bias related to out-of-sequence vaccination.
2.5. Statistical methods
We used Cox regression to estimate the incidence rate ratios
(IRRs) and 95% CIs of infectious disease hospital admissions
according to the most recent vaccine by including vaccination sta-
tus as a time-varying variable. This means that the children chan-
ged vaccination group at the date of vaccination. The main
comparison was between simultaneous MMR and DTaP-IPV-Hib
vs. MMR alone as most recent vaccine, but we also compared
simultaneous MMR and DTaP-IPV-Hib vs. DTaP-IPV-Hib alone as
most recent vaccine and DTaP-IPV-Hib alone vs. MMR alone as
most recent vaccine. The assumption of proportional hazards
between simultaneous MMR and DTaP-IPV-Hib and MMR alone
was evaluated by Schoenfeld residuals, and no violations were
detected. We used age as the underlying timescale and stratified
by date of birth (day, month, and year) to control completely for
any effect of age, season, and calendar year. All infectious disease
admissions were included, so children may contribute with several
admissions. However, several admissions within a short time per-
iod could be related to the same infection, therefore we defined
admissions occurring within 14 days after a previous discharge
as the same episode. Accordingly, person time during admission
and 14 days after discharge was not included in the count of per-
son years. To account for recurrent admissions for infections, we
used the Andersen-Gill model, where the main assumption is, that
the effects of covariates on the intensity (incidence rate) for events,
is similar for the first event, second event and so forth. Notably, we
employ a Markov version of the Andersen-Gill model because we
assume that time since previous events does not affect the inten-
sity of future events in our model [21]. We performed both unad-
justed and adjusted analyses in Stata 13.
We performed the analyses separately according to type of
infection, duration of admission, and age groups. Furthermore,
we examined whether the association between vaccination status
and admissions with infections differed according to determinants
of simultaneous MMR and DTaP-IPV-Hib and tested for homogene-
ity with Wald test statistics.
2.5.1. Sensitivity analyses
We performed a number of sensitivity analyses further
described in supplemental methods.
2.5.2. Negative control outcome
We do not believe vaccination status is causally related to
emergency room visits due to unintentional accidents and would
not expect any association. Therefore, we performed an analysis
with emergency room visits due to unintentional accidents as neg-
ative control outcome [22] to examine if differential health seeking
behaviour could explain any association between vaccination sta-
tus and infectious disease admissions.
3. Results
3.1. Inclusion and censoring
The study included 520,859 children (Fig. 1); the majority were
followed from age 15 months, but 1991 (0.4%) received their first
vaccine after 15 months of age and were followed from the date
of the first vaccination. Follow-up ended at age 4 years
(N = 305,802; 58.7%), administration of other vaccines than
MMR1 and DTaP-IPV-Hib (mainly OPV) (N = 140,554; 27.0%), 1 Jan-
uary 2009 (N = 72,022; 13.8%), migration (N = 2274; 0.4%), death
(N = 144; 0.0%), unknown whereabouts for the Danish authorities
(N = 50; 0.0%), and uncertain vaccine allocation for twins or triplets
(N = 13; 0.0%).
The vaccination history of the children is presented in Fig. 2. The
MMR group consisted mainly of children who followed the recom-
mended schedule and first received three doses of DTaP-IPV-Hib
and later MMR. The group receiving simultaneous MMR and
DTaP-IPV-Hib consisted mainly of children who received MMR
and DTaP-IPV-Hib3 simultaneously.
56,560 children were included in the ‘‘DTaP-IPV-Hib-2-sub
group” receiving either MMR alone (N = 51,256; 90.6%) or simulta-
neous MMR and DTaP-IPV-Hib3 (N = 5304; 9.4%) after DTaP-IPV-
Hib2.
3.2. Determinants of vaccination
By 2 years of age, most children had reached their final vaccina-
tion group; 4965 children had simultaneous MMR and DTaP-IPV-
Hib (1.0%), 411,518 had MMR alone (83.7%) and 74,959 had
DTaP-IPV-Hib alone (15.3%) as the most recent vaccine. The distri-
bution of background factors according to the most recent vaccine
at 2 years of age are given in Table 1.
3.3. Hospital admissions due to infectious diseases
The study included 71,766 infectious disease admissions during
1,119,757 person-years at risk (rate, 6.4 admissions per 100
person-years). The rates of admissions according to vaccination
history are given in Fig. 2. The rate of infectious disease admissions
declined with age for all three vaccine groups (Supplemental
Fig. 1).
Compared with MMR alone, simultaneous administration of
MMR and DTaP-IPV-Hib was associated with a higher rate of infec-
tious disease admissions for all children (adjusted IRR, 1.07; 95% CI,
1.00–1.15; Table 2a). The estimate was the same in the ‘‘DTaP-IPV-
Hib-2-subgroup” (adjusted IRR, 1.07; 95% CI, 0.98–1.16; Table 2b).
For all children, comparing simultaneous MMR and DTaP-IPV-
Hib with DTaP-IPV-Hib alone there was no difference (adjusted
IRR, 0.95; 95% CI, 0.89–1.02; p, 0.166).
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3.4. Type of infection, duration of admission, age groups and
interactions
The rate of admission for lower respiratory tract infections was
significantly higher for simultaneous MMR and DTaP-IPV-Hib com-
pared with MMR alone for all children (adjusted IRR, 1.27; 95% CI,
1.13–1.42; Table 3a) and in the ‘‘DTaP-IPV-Hib-2-subgroup”
(adjusted IRR, 1.22; 95% CI, 1.05–1.42; Table 3b). There were no
significant differences between the two vaccine groups for any
other types of infections (Table 3a and b).
26,621 admissions lasted less than one day (37.1%). IRRs com-
paring simultaneous MMR and DTaP-IPV-Hib with MMR alone as
most recent vaccine were similar irrespective of duration of admis-
sion, both when considering admissions with any type of infection
(Supplemental Table 2a) or only admissions with lower respiratory
tract infections (Supplemental Table 2b).
Effect estimates for any infection and for lower respiratory tract
infections were similar in all age groups during follow-up (Supple-
mental Table 3a and b).
Interactions were only examined in relation to admissions due
to lower respiratory tract infections as this was the only type of
infection with significant association to simultaneous administra-
tion of MMR and DTaP-IPV-Hib. The association between simulta-
neous administration of MMR and DTaP-IPV-Hib and admissions
with lower respiratory tract infections was significantly stronger
for children who had been admitted with infections before
15 months of age (IRR = 1.59; 95% CI, 1.35–1.87) compared with
those not admitted (IRR = 1.13; 95% CI, 0.96–1.34; Supplemental
Table 4). The association was also significantly stronger for chil-
dren of mothers with an educational level above vocational train-
ing (IRR = 1.61; 95% CI, 1.32–1.95) compared with children of less
educated mothers (IRR = 1.14; 95% CI, 0.98–1.31; Supplemental
Table 4). The association was stronger for children from high-
income households (IRR = 1.56; 95% CI, 1.30–1.87) compared with
low-income households (IRR = 1.11; 95% CI, 0.95–1.30; Supple-
mental Table 4). Furthermore, the association was only present
in children from areas with less than 2000 inhabitants per km2
(IRR = 1.36; 95% CI, 1.19–1.55) compared with areas with more
inhabitants (IRR = 1.03; 95% CI, 0.80–1.31; Supplemental Table 4).
3.5. Sensitivity analyses
None of the sensitivity analyses altered the results considerably
as further described in Supplemental results.
3.6. Negative control outcome
There was no difference in the rate of emergency room visits
due to accidents for children who had simultaneous MMR and
DTaP-IPV-Hib compared with MMR alone (adjusted IRR, 1.00;
95% CI, 0.95–1.04; Table 4).
Fig. 2. Rate of infectious disease admissions according to most recent vaccine and vaccination history. Abbreviations: DTaP-IPV-Hib, vaccination against diphtheria, tetanus,
pertussis (acellular), polio, and Haemophilus influenzae type b; MMR, vaccination against measles, mumps, and rubella; LRTI, admissions with lower respiratory tract
infections. The rate is the incidence rate of infectious disease admissions (any) and separately for admissions with lower respiratory tract infections (LRTI) per 100 person-
years according to the most recent vaccine and previous vaccination history for the children included in the study. In brackets number of admission/person-years. The figure
only includes admissions and person-years from the date of inclusion in the study (15 months of age for the majority). Thus for instance the incidence rate in the box DTaP-
IPV-Hib1 are the rate in the age interval 15 months–4 years for children who have not yet received any other vaccines. Light blue boxes mark the cases and person years
included in the overall MMR + DTaP-IPV-Hib group; Light green boxes mark the cases and person years included in the overall MMR group; the ‘‘DTaP-IPV-Hib-2-subgroup”
box contains the individuals included in the subgroup analyses. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.)
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Table 1
Distribution of vaccinations at 2 years of age according to background factors.
All Children ‘‘DTaP-IPV-Hib-2-subgroup”a
Simultaneous MMR and
DTaP-IPV-Hib % (N)
DTaP-IPV-Hib alone
% (N)
MMR alone
% (N)
Simultaneous MMR and
DTaP-IPV-Hib3 % (N)
MMR alone
% (N)
Maternal smoking during pregnancy
No 76.8%
(3815)
74.0%
(55,465)
82.7%
(340,486)
77.1%
(3323)
82.0%
(35,603)
Yes 23.2%
(1150)
26.0%
(19,494)
17.3%
(71,032)
22.9%
(988)
18.0%
(7799)
Sex
Male 53.2%
(2643)
52.3%
(39,208)
50.9%
(209,376)
53.2%
(2295)
51.6%
(22,406)
Female 46.8%
(2322)
47.7%
(35,751)
49.1%
(202,142)
46.8%
(2016)
48.4%
(20,996)
Birth weight, g
62000 2.4%
(117)
2.0%
(1531)
1.8%
(7415)
2.2%
(96)
2.0%
(863)
2001–2500 3.1%
(156)
3.4%
(2572)
3.2%
(13,216)
3.2%
(137)
3.3%
(1421)
2501–3000 12.4%
(616)
12.3%
(9254)
12.0%
(49,431)
12.2%
(526)
12.0%
(5222)
3001–3500 31.2%
(1550)
31.3%
(23,447)
31.6%
(129,903)
31.0%
(1335)
31.6%
(13,726)
3501–4000 32.4%
(1609)
33.0%
(24,747)
33.6%
(138,098)
32.9%
(1417)
33.3%
(14,447)
4001–4500 15.2%
(753)
14.4%
(10,790)
14.4%
(59,358)
15.3%
(659)
14.3%
(6214)
>4500 3.3%
(164)
3.5%
(2618)
3.4%
(14,097)
3.3%
(141)
3.5%
(1509)
Gestational age, weeks
<37 7.1%
(354)
6.3%
(4747)
6.0%
(24,875)
6.9%
(298)
6.3%
(2730)
P37 92.9%
(4611)
93.7%
(70,212)
94.0%
(386,643)
93.1%
(4013)
93.7%
(40,672)
Caesarean section
No 81.8%
(4062)
83.0%
(62,238)
82.3%
(338,734)
81.7%
(3522)
81.7%
(35,473)
Yes 18.2%
(903)
17.0%
(12,721)
17.7%
(72,784)
18.3%
(789)
18.3%
(7929)
Chronic diseases
No 96.3%
(4779)
96.0%
(71,971)
97.0%
(398,975)
96.3%
(4153)
96.7%
(41,988)
Yes 3.7%
(186)
4.0%
(2988)
3.0%
(12,543)
3.7%
(158)
3.3%
(1414)
Number of admissions due to infections before 15 months of age
None 82.6%
(4099)
84.4%
(63,285)
87.7%
(360,981)
82.7%
(3567)
86.9%
(37,733)
One 14.0%
(694)
12.6%
(9430)
10.4%
(42,941)
13.9%
(601)
11.1%
(4798)
Two 2.4%
(121)
2.2%
(1669)
1.5%
(6016)
2.3%
(99)
1.6%
(681)
Three or more 1.0%
(51)
0.8%
(575)
0.4%
(1580)
1.0%
(44)
0.4%
(190)
Admitted to hospital for any cause within the last month
No 98.8%
(4906)
98.8%
(74,039)
99.1%
(407,741)
98.9%
(4262)
99.0%
(42,961)
Yes 1.2%
(59)
1.2%
(920)
0.9%
(3777)
1.1%
(49)
1.0%
(441)
Maternal age at birth of the child, years
619 1.8%
(91)
2.0%
(1522)
1.3%
(5327)
1.8%
(78)
1.5%
(651)
20–24 12.1%
(602)
13.0%
(9722)
11.6%
(47,603)
11.7%
(503)
12.0%
(5210)
25–29 32.8%
(1631)
32.5%
(24,363)
36.2%
(148,876)
32.4%
(1398)
35.4%
(15,378)
30–34 36.3%
(1804)
34.6%
(25,938)
35.6%
(146,585)
37.0%
(1596)
35.5%
(15,401)
35–39 14.4%
(716)
15.3%
(11,458)
13.4%
(55,238)
14.5%
(626)
13.7%
(5939)
P40 2.4%
(121)
2.6%
(1956)
1.9%
(7889)
2.6%
(110)
1.9%
(823)
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4. Discussion
The rate of hospital admissions related to infectious diseases
was higher when the most recent vaccination was simultaneous
MMR and DTaP-IPV-Hib compared with MMR alone as the most
recent vaccine. This was due to a higher rate of lower respiratory
tract infections, but not other types of infections. There was no dif-
ference in the rate of hospital admission for any infectious disease
or for lower respiratory tract infections when comparing simulta-
neous MMR and DTaP-IPV-Hib with DTaP-IPV-Hib alone.
The present study included all children born in Denmark and
follow-up was nearly complete due to the high quality of the Dan-
ish population based registries [11]. We believe that the vaccina-
tion information is reliable because it was reported by general
practitioners for reimbursement purposes, but we cannot exclude
some underreporting [23].
Several issues indicate that bias is unlikely to explain the asso-
ciation between simultaneous administration of MMR and DTaP-
IPV-Hib and admissions due to lower respiratory tract infections.
First, we took several steps to minimize confounding. We adjusted
Table 1 (continued)
All Children ‘‘DTaP-IPV-Hib-2-subgroup”a
Simultaneous MMR and
DTaP-IPV-Hib % (N)
DTaP-IPV-Hib alone
% (N)
MMR alone
% (N)
Simultaneous MMR and
DTaP-IPV-Hib3 % (N)
MMR alone
% (N)
Highest educational level for the female adult in the household
Primary school 26.7%
(1328)
27.9%
(20,883)
18.7%
(76,975)
25.4%
(1096)
20.2%
(8779)
High school examination 9.9%
(494)
9.9%
(7410)
9.8%
(40,448)
9.8%
(422)
9.8%
(4234)
Vocational training 28.5%
(1415)
31.0%
(23,235)
34.7%
(142,751)
29.1%
(1254)
33.5%
(14,530)
Bachelor or academy profession 26.1%
(1294)
24.7%
(18,504)
28.1%
(115,660)
26.9%
(1158)
27.8%
(12,054)
Master’s degree or higher 8.7%
(434)
6.6%
(4927)
8.7%
(35,684)
8.8%
(381)
8.8%
(3805)
Parental place of birth
Denmark 78.8%
(3911)
82.7%
(61,981)
83.6%
(343,912)
79.7%
(3435)
82.6%
(35,856)
Denmark and foreign 10.4%
(515)
9.6%
(7163)
8.8%
(36,251)
10.0%
(430)
9.0%
(3903)
Foreign 10.9%
(539)
7.8%
(5815)
7.6%
(31,355)
10.3%
(446)
8.4%
(3643)
Adults in the household
Two adults 88.7%
(4403)
88.5%
(66,327)
93.6%
(385,021)
88.9%
(3831)
92.5%
(40,161)
Single parent 11.3%
(560)
11.5%
(8601)
6.4%
(26,418)
11.1%
(478)
7.4%
(3228)
No parents 0.0%
(2)
0.0%
(31)
0.0%
(79)
0.0%
(2)
0.0%
(13)
Income quintiles for the household
1st (lowest) 26.3%
(1305)
26.5%
(19,877)
17.2%
(70,966)
25.2%
(1087)
19.4%
(8401)
2nd 20.2%
(1004)
22.2%
(16,647)
19.0%
(78,374)
20.0%
(862)
19.2%
(8353)
3rd 19.4%
(964)
19.1%
(14,327)
20.8%
(85,481)
19.9%
(858)
20.3%
(8799)
4th 17.3%
(857)
16.9%
(12,634)
21.6%
(88,933)
17.8%
(767)
20.6%
(8930)
5th (highest) 16.8%
(835)
15.3%
(11,474)
21.3%
(87,764)
17.1%
(737)
20.5%
(8919)
Other children in the household
No 26.0%
(1291)
28.0%
(20,965)
42.8%
(176,099)
26.5%
(1142)
41.1%
(17,857)
Yes 74.0%
(3674)
72.0%
(53,994)
57.2%
(235,419)
73.5%
(3169)
58.9%
(25,545)
Population density, inhabitants per km2
<50 5.1%
(253)
8.2%
(6152)
6.6%
(27,188)
5.0%
(214)
6.7%
(2918)
50–499 56.2%
(2788)
59.9%
(44,871)
58.9%
(242,240)
56.6%
(2440)
60.2%
(26,144)
500–1999 16.3%
(811)
16.7%
(12,553)
18.7%
(76,926)
16.3%
(704)
17.6%
(7654)
2000–4999 5.6%
(278)
4.2%
(3178)
4.5%
(18,629)
5.5%
(237)
4.4%
(1927)
P5000 16.8%
(835)
10.9%
(8205)
11.3%
(46,535)
16.6%
(716)
11.0%
(4759)
Abbreviations: MMR, vaccination against measles, mumps, and rubella; DTaP-IPV-Hib, vaccination against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus
influenzae type b.
a Children who have received DTaP-IPV-Hib1 and DTaP-IPV-Hib2 previously and thereafter either simultaneous MMR and DTaP-IPV-Hib3 or MMR alone.
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for a long range of potential confounders including complete
adjustment for age. However, there might be other factors associ-
ated both with lack of compliance with the recommended vaccina-
tion schedule and infectious disease admissions which we had no
information about. Therefore, we performed a separate analysis
for the ‘‘DTaP-IPV-Hib-2-subgroup” of children who received vac-
cines out-of-sequence after DTaP-IPV-Hib2 and found a similar
association. There were however still marked differences in
Table 3
Results for admissions with different types of infections according to most recent vaccine.
Admissions per 100 person-years
(Admissions/Person-years)
Unadjusted IRRa (95% CI) Adjusted IRR b (95% CI)
(a) All children
Upper respiratory tract infections
Simultaneous MMR and DTaP-IPV-Hib 2.6 (329/12,591) 1.16 (1.04–1.29) 1.01 (0.90–1.13)
DTaP-IPV-Hib alone 3.8 (7453/196,464) 1.24 (1.20–1.28) 1.12 (1.08–1.15)
MMR alone 2.3 (21,129/910,702) 1 (ref) 1 (ref)
Lower respiratory tract infections
Simultaneous MMR and DTaP-IPV-Hib 2.4 (308/12,591) 1.58 (1.41–1.77) 1.27 (1.13–1.42)
DTaP-IPV-Hib alone 3.4 (6657/196,464) 1.43 (1.38–1.47) 1.22 (1.18–1.26)
MMR alone 1.7 (15,292/910,702) 1 (ref) 1 (ref)
Gastrointestinal infections
Simultaneous MMR and DTaP-IPV-Hib 0.8 (106/12,591) 1.01 (0.84–1.23) 0.94 (0.77–1.14)
DTaP-IPV-Hib alone 1.3 (2494/196,464) 1.13 (1.08–1.19) 1.07 (1.01–1.12)
MMR alone 0.8 (7573/910,702) 1 (ref) 1 (ref)
Other types
Simultaneous MMR and DTaP-IPV-Hib 1.5 (189/12,591) 1.13 (0.98–1.31) 1.00 (0.87–1.16)
DTaP-IPV-Hib alone 2.1 (4138/196,464) 1.22 (1.18–1.27) 1.07 (1.03–1.12)
MMR alone 1.3 (12,266/910,702) 1 (ref) 1 (ref)
(b) ‘‘DTaP-IPV-Hib-2-subgroup”c
Upper respiratory tract infections
Simultaneous MMR and DTaP-IPV-Hib3 2.6 (285/10,912) 1.12 (0.99–1.28) 1.04 (0.90–1.19)
MMR alone 2.5 (2440/98,371) 1 (ref) 1 (ref)
Lower respiratory tract infections
Simultaneous MMR and DTaP-IPV-Hib3 2.4 (266/10,912) 1.49 (1.29–1.70) 1.22 (1.05–1.42)
MMR alone 1.8 (1780/98,371) 1 (ref) 1 (ref)
Gastrointestinal infections
Simultaneous MMR and DTaP-IPV-Hib3 0.9 (94/10,912) 1.03 (0.82–1.28) 0.99 (0.79–1.25)
MMR alone 0.9 (878/98,371) 1 (ref) 1 (ref)
Other types
Simultaneous MMR and DTaP-IPV-Hib3 1.4 (154/10,912) 1.04 (0.88–1.24) 0.93 (0.77–1.12)
MMR alone 1.4 (1390/98,371) 1 (ref) 1 (ref)
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; DTaP-IPV-Hib, vaccination against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae
type b; MMR, vaccination against measles, mumps, and rubella.
a Cox proportional hazards model with age as underlying time and stratified by date of birth thereby controlling for season.
b Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for mother smoking during pregnancy, sex, birth weight, gestational
age, caesarean section, chronic diseases, number of infectious disease admissions before 15 months of age, admitted to hospital for any cause within the last 30 days,
maternal age at birth of the child, highest educational level for the female adult in the household, parental place of birth, adults in the household, income quintiles for the
household, other children in the household, and population density.
c Children who have received DTaP-IPV-Hib1 and DTaP-IPV-Hib2 previously and thereafter either simultaneous MMR and DTaP-IPV-Hib3 or MMR alone.
Table 2
Incidence and incidence rate ratios of admissions with infections according to the most recent vaccination.
Admissions per 100 person-years
(Admissions/Person-years)
Unadjusted IRRa
(95% CI)
P value Adjusted IRRb
(95% CI)
P value
(a) All children
Simultaneous MMR and DTaP-IPV-Hib 6.8 (862/12,591) 1.24 (1.16–1.33) 1.07 (1.00–1.15)c
DTaP-IPV-Hib alone 9.6 (18,829/196,464) 1.26 (1.24–1.29) <0.001 1.13 (1.11–1.15) <0.001
MMR alone 5.7 (52,075/910,702) 1(ref) 1(ref)
(b) ‘‘DTaP-IPV-Hib-2-subgroup”d
Simultaneous MMR and DTaP-IPV-Hib3 6.7 (736/10,912) 1.19 (1.10–1.29) <0.001 1.07 (0.98–1.16) 0.139
MMR alone 6.1 (5958/98,371) 1(ref) 1(ref)
Abbreviations: DTaP-IPV-Hib, vaccination against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae type b; MMR, vaccination against measles,
mumps, and rubella; IRR, incidence rate ratio; CI, confidence interval.
a Cox proportional hazards model with age as underlying time scale and stratified by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for mother smoking during pregnancy, sex, birth weight, gestational
age, caesarean section, chronic diseases, number of infectious disease admissions before 15 months of age, admitted to hospital for any cause within the last 30 days,
maternal age at birth of the child, highest educational level for the female adult in the household, parental place of birth, adults in the household, income quintiles for the
household, other children in the household, and population density.
c p-value 0.045.
d Children who have received DTaP-IPV-Hib1 and DTaP-IPV-Hib2 previously and thereafter either simultaneous MMR and DTaP-IPV-Hib3 or MMR alone.
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background factors between those who received MMR alone and
those who received simultaneous MMR and DTaP-IPV-Hib3 within
this subgroup. This might be related to underreporting of DTaP-
IPV-Hib-3 leading to some children being included in the ‘‘DTaP-I
PV-Hib-2-subgroup” although they have received DTaP-IPV-Hib-
3. Such children would only be eligible to receive MMR, while chil-
dren truly delayed on DTaP-IPV-Hib-3 would be eligible to receive
MMR and DTaP-IPV-Hib-3 simultaneously. If this should influence
the results delay on DTaP-IPV-Hib-3 should be related to some
health or other background factor, which is not already captured
by the many background factors we adjust for. Second, the associ-
ation was only observed for admissions with lower respiratory
tract infections, but not for other infectious disease groups. It is dif-
ficult to imagine a confounder or other social, economic, cultural or
health bias, which would lead to simultaneous administration of
MMR and DTaP-IPV-Hib being associated with higher admission
rates due to lower respiratory tract infections, but not with other
types of infections. Third, it is unlikely that the results could be
explained by differences in health seeking behaviour, as vaccina-
tion status was not related to emergency room visits due to unin-
tentional accidents.
Similar results have been observed in other settings. A random-
ized trial from Guinea-Bissau showed detrimental effects of simul-
taneous administration of DTP, OPV, and measles vaccine
compared with OPV and measles vaccine alone on ‘‘febrile disease
with vesicular rash” reported by the mother (IRR, 1.86; 95% CI,
1.00–3.47); this trial also found a tendency toward increased risk
of hospital admission for any cause (IRR, 1.70; 95% CI, 0.70–4.07)
[24]. Several observational studies from low-income countries
have found detrimental effects on mortality and admissions with
simultaneous administration of live measles vaccine and inacti-
vated DTP vaccine [6–8,25–27]. Previous studies, including a ran-
domized trial, have shown that measles vaccine has the strongest
effects related to the prevention of admissions for lower respira-
tory tract infections [1,28,29].
The biological mechanisms explaining the present findings have
not been determined, but the non-specific effects of vaccines have
been linked to both heterologous immunity due to cross-reactive
T- and B-cell epitopes and training of the innate immune system
[2,4,5,30]. For example, the live Bacille Calmette-Guerin vaccine
can induce epigenetic changes which reprograms monocytes to
enhanced protection against unrelated pathogens [31]. It is
unknown whether simultaneous administration of MMR and
DTaP-IPV-Hib may neutralise the beneficial effect of MMR vaccine
for lower respiratory tract infections or DTaP-IPV-Hib increases
susceptibility to pathogens of the lower respiratory tract.
Vaccination schedules have been designed based on studies of
specific immune responses [32], and assessment of specific vaccine
efficacy and not on studies of impact on overall morbidity and
mortality [33]. Vaccines are often administered together due to
convenience and to achieve higher vaccination coverage. However,
in the context of herd immunity toward the targeted diseases it
might also affect the overall health of children as suggested by
the present study. WHO’s Strategic Advisory Group of Experts on
immunization (SAGE) has stated that further research into non-
specific effects of vaccines are warranted and particularly recom-
mend randomized trials [34]. The present study suggests that in
countries where the vaccination schedule includes simultaneous
administration of MMR and DTaP-IPV-Hib it would be important
to test the recommended schedule against a schedule with MMR
administered after DTaP-IPV-Hib. However, additional observa-
tional studies are also needed to examine non-specific effects in
other settings and to help optimize the design of subsequent ran-
domized trials.
5. Conclusions
As hypothesized, simultaneous administration of MMR and
DTaP-IPV-Hib vaccine was associated with a higher rate of infec-
tious disease admissions compared with MMR alone as the most
recent vaccine. The association was only significant for lower res-
piratory tract infections, but not for other types of infections. Even
though it might be convenient to administer vaccines together, it
may have negative effects on the overall health of children com-
pared with the live vaccine alone in the context of herd immunity
to the targeted diseases. This needs to be examined further in
observational studies and randomized trials.
Conflict of interest
None.
Funding
This work was supported by the Danish Council for Independent
Research [DFF – 4183-00316 to S.S.]; the Health Foundation
(Helsefonden) [2009B132 to S.S.]; Rosalie Petersens Foundation
[to S.S.]; the Novo Nordisk Foundation [research professorship
grant to P.A.]; European Research Council (ERC) Starting Grant
[ERC-StG-243149 to C.S.B]; and the Danish National Research
Foundation (DNRF) supports the Research Center for Vitamins
and Vaccines [DNRF108]. The funding bodies had no role in the
design of the study and collection, analysis, and interpretation of
data and in writing of the manuscript.
Authors’ contributions
S.S., C.S.B., A.P., T.G.K., P.A., and H.R. conceptualized and
designed the study. S.S. and H.R. acquired the data and performed
Table 4
Incidence and incidence rate ratios of unintentional accidents according to the most recent vaccination.
Characteristics Accidents per 100 person-
years (Accidents/Person-
years)
Unadjusted IRRa (95% CI) P value Adjusted IRRb (95% CI) P value
Simultaneous MMR and DTaP-IPV-Hib 14.9 (1872/12,557) 1.08 (1.03–1.13) 1.00 (0.95–1.04)
DTaP-IPV-Hib alone 14.7 (28,926/196,220) 1.04 (1.03–1.05) <0.001 1.01 (0.99–1.02) 0.721
MMR alone 14.1 (128,166/908,150) 1(ref) 1(ref)
Abbreviations: DTaP-IPV-Hib, vaccination against diphtheria, tetanus, pertussis (acellular), polio, and Haemophilus influenzae type b; MMR, vaccination against measles,
mumps, and rubella; IRR, incidence rate ratio; CI, confidence interval.
a Cox proportional hazards model with age as underlying time scale and stratified by date of birth thereby controlling for age and season.
b Cox proportional hazards model with age as underlying time, stratified by date of birth and adjusted for mother smoking during pregnancy, sex, birth weight, gestational
age, caesarean section, chronic diseases, number of infectious disease admissions before 15 months of age, admitted to hospital for any cause within the last 30 days,
maternal age at birth of the child, highest educational level for the female adult in the household, parental place of birth, adults in the household, income quintiles for the
household, other children in the household, and population density.
S. Sørup et al. / Vaccine 34 (2016) 6172–6180 6179
the statistical analyses. S.S., C.S.B., A.P., T.G.K., P.A., and H.R. anal-
ysed and interpreted the data. S.S. drafted the initial manuscript.
C.S.B., A.P., T.G.K., P.A., and H.R. critically revised the manuscript
for important intellectual content. All authors approved the final
submitted version.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.11.
005.
References
[1] Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against
measles, mumps, and rubella and the risk of hospital admissions for
nontargeted infections. JAMA 2014;311:826–35. doi: http://dx.doi.org/
10.1001/jama.2014.470.
[2] Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific
immunomodulation by vaccines. Trends Immunol 2013;34:431–9. doi: http://
dx.doi.org/10.1016/j.it.2013.04.004.
[3] Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, et al. Non-
specific effects of standard measles vaccine at 4.5 and 9 months of age on
childhood mortality: randomised controlled trial. BMJ 2010;341:c6495. doi:
http://dx.doi.org/10.1136/Bmj.C6495.
[4] Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant
vaccination: public-health, immunological and conceptual challenges. Nat
Immunol 2014;15:895–9. doi: http://dx.doi.org/10.1038/ni.2961.
[5] Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O, Optimmunize N.
Heterologous (‘‘nonspecific”) and sex-differential effects of vaccines:
epidemiology, clinical trials, and emerging immunologic mechanisms. Clin
Infect Dis 2013;57:283–9. doi: http://dx.doi.org/10.1093/cid/cit209.
[6] Aaby P, Ibrahim SA, Libman MD, Jensen H. The sequence of vaccinations and
increased female mortality after high-titre measles vaccine: trials from rural
Sudan and Kinshasa. Vaccine 2006;24:2764–71. doi: http://dx.doi.org/
10.1016/j.vaccine.2006.01.004.
[7] Aaby P, Vessari H, Nielsen J, Maleta K, Benn CS, Jensen H, et al. Sex differential
effects of routine immunizations and childhood survival in rural Malawi.
Pediatr Infect Dis J 2006;25:721–7.
[8] Aaby P, Jensen H, Walraven G. Age-specific changes in the female-male
mortality ratio related to the pattern of vaccinations: an observational study
from rural Gambia. Vaccine 2006;24:4701–8. doi: http://dx.doi.org/10.1016/
j.vaccine.2006.03.038.
[9] Control ECfDPa. Vaccine schedule European Centre for Disease Prevention and
Control; 2015.
[10] Prevention CfDCa. 2015 Recommended immunizations for children from birth
through 6 years old. Centers for Disease Control and Prevention; 2015.
[11] Pedersen CB. The Danish civil registration system. Scand J Public Health
2011;39:22–5. doi: http://dx.doi.org/10.1177/1403494810387965.
[12] Valentiner-Branth P, Andersen PH, Chrsistiansen AH, Vestergaard L, Glismann
S, Christensen JJ, et al. Pneumokokvaccine i børnevaccinationsprogrammet.
EPI-NYT 2007:37a.
[13] Thygesen LC, Ersboll AK. Danish population-based registers for public health
and health-related welfare research: introduction to the supplement. Scand J
Public Health 2011;39:8–10. doi: http://dx.doi.org/10.1177/
1403494811409654.
[14] Andersen JS, Olivarius NDF, Krasnik A. The Danish national health service
register. Scand J Public Health 2011;39:34–7. doi: http://dx.doi.org/10.1177/
1403494810394718.
[15] Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J
Public Health 2011;39:30–3. doi: http://dx.doi.org/10.1177/
1403494811401482.
[16] Davis K. The Danish health system through an American lens. Health Policy
2002;59:119–32.
[17] Kristensen K, Hjuler T, Ravn H, Simoes EA, Stensballe LG. Chronic diseases,
chromosomal abnormalities, and congenital malformations as risk factors for
respiratory syncytial virus hospitalization: a population-based cohort study.
Clin Infect Dis 2012;54:810–7. doi: http://dx.doi.org/10.1093/cid/cir928.
[18] Knudsen LB, Olsen J. The Danish medical birth registry. Dan Med Bull
1998;45:320–3.
[19] Baadsgaard M, Quitzau J. Danish registers on personal income and transfer
payments. Scand J Public Health 2011;39:103–5. doi: http://dx.doi.org/
10.1177/1403494811405098.
[20] Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health
2011;39:91–4. doi: http://dx.doi.org/10.1177/1403494810394715.
[21] Cook RJ, Lawless JF. General intensity-based models. In: The statistical analysis
of recurrent events. New York: Springer; 2007. p. 161–204.
[22] Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for
detecting confounding and bias in observational studies. Epidemiology
2010;21:383–8. doi: http://dx.doi.org/10.1097/EDE.0b013e3181d61eeb.
[23] Wojcik OP, Simonsen J, Molbak K, Valentiner-Branth P. Validation of the 5-year
tetanus, diphtheria, pertussis and polio booster vaccination in the Danish
childhood vaccination database. Vaccine 2013;31:955–9. doi: http://dx.doi.
org/10.1016/j.vaccine.2012.11.100.
[24] Agergaard J, Nante E, Poulstrup G, Nielsen J, Flanagan KL, Ostergaard L, et al.
Diphtheria-tetanus-pertussis vaccine administered simultaneously with
measles vaccine is associated with increased morbidity and poor growth in
girls. A randomised trial from Guinea-Bissau. Vaccine 2011;29:487–500.
[25] Aaby P, Biai S, Veirum JE, Sodemann M, Lisse I, Garly ML, et al. DTP with or
after measles vaccination is associated with increased in-hospital mortality in
Guinea-Bissau. Vaccine 2007;25:1265–9. doi: http://dx.doi.org/10.1016/
j.vaccine.2006.10.007. pii:S0264-410X(06)01111-X.
[26] Hirve S, Bavdekar A, Juvekar S, Benn CS, Nielsen J, Aaby P. Non-specific and
sex-differential effects of vaccinations on child survival in rural western India.
Vaccine 2012;30:7300–8. doi: http://dx.doi.org/10.1016/
j.vaccine.2012.09.035.
[27] Biai S, Rodrigues A, Nielsen J, Sodemann M, Aaby P. Vaccination status and
sequence of vaccinations as risk factors for hospitalisation among outpatients
in a high mortality country. Vaccine 2011;29:3662–9. doi: http://dx.doi.org/
10.1016/j.vaccine.2011.03.016.
[28] Veirum JE, Sodemann M, Biai S, Jakobsen M, Garly ML, Hedegaard K, et al.
Routine vaccinations associated with divergent effects on female and male
mortality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine
2005;23:1197–204. doi: http://dx.doi.org/10.1016/j.vaccine.2004.02.053.
[29] Martins CL, Benn CS, Andersen A, Bale C, Schaltz-Buchholzer F, Do VA, et al. A
randomized trial of a standard dose of Edmonston-Zagreb measles vaccine
given at 4.5 months of age: effect on total hospital admissions. J Infect Dis
2014;209:1731–8. doi: http://dx.doi.org/10.1093/infdis/jit804.
[30] Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between
viruses. Immunol Rev 2010;235:244–66. doi: http://dx.doi.org/10.1111/
j.0105-2896.2010.00897.x.
[31] Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille
Calmette-Guerin induces NOD2-dependent nonspecific protection from
reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci
USA 2012;109:17537–42. doi: http://dx.doi.org/10.1073/pnas.1202870109.
[32] Aaby P, Martins CL, Garly ML, Rodrigues A, Benn CS, Whittle H. The optimal age
of measles immunisation in low-income countries: a secondary analysis of the
assumptions underlying the current policy. BMJ Open 2012;2:e000761. doi:
http://dx.doi.org/10.1136/bmjopen-2011-000761.
[33] Aaby P, Whittle H, Benn CS. Vaccine programmes must consider their effect on
general resistance. BMJ 2012;344:e3769. doi: http://dx.doi.org/10.1136/bmj.
e3769.
[34] Meeting of the Strategic Advisory Group of Experts on immunization, April
2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014;2014
(89):221–36.
6180 S. Sørup et al. / Vaccine 34 (2016) 6172–6180
